Acute lymphocytic leukemia First Relapse | Bone Marrow Involvement with | Leukemic Blast Count | Disease Extramedullary | Philadelphia chromosome positive
Item
patients with acute lymphoblastic leukemia (all) in first relapse involving the bone marrow (m3 marrow), with or without associated extramedullary disease; this includes patients who are philadelphia chromosome-positive
boolean
C0023449 (UMLS CUI [1,1])
C4054953 (UMLS CUI [1,2])
C0005953 (UMLS CUI [2,1])
C1314939 (UMLS CUI [2,2])
C2697913 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C1517060 (UMLS CUI [4,2])
C0856536 (UMLS CUI [5])
Shortening Fraction | Echocardiogram | Cardiac ejection fraction | Gated Blood-Pool Imaging
Item
shortening fraction of >= 28% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
boolean
C1335957 (UMLS CUI [1])
C2243117 (UMLS CUI [2])
C0232174 (UMLS CUI [3])
C0017200 (UMLS CUI [4])
Anthracycline Previous Cumulative Exposure to | Idarubicin | Daunorubicin | Adriamycin
Item
cumulative prior anthracycline exposure of =< 350 mg/m^2 (each 10 mg/m^2 dose of idarubicin should be calculated as the isotoxic equivalent of 50 mg/m^2 of daunorubicin or adriamycin)
boolean
C0282564 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C1511559 (UMLS CUI [1,3])
C0332157 (UMLS CUI [1,4])
C0020789 (UMLS CUI [2])
C0011015 (UMLS CUI [3])
C0085752 (UMLS CUI [4])
Informed Consent | Informed Consent parent | Informed Consent Legal Guardians
Item
all patients and/or their parents or legal guardians must sign a written informed consent
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030551 (UMLS CUI [2,2])
C0021430 (UMLS CUI [3,1])
C0023226 (UMLS CUI [3,2])
Clinical Research criteria Fulfill
Item
all institutional, food and drug administration (fda), and national cancer institute (nci) requirements for human studies must be met
boolean
C0008972 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
B-cell childhood acute lymphoblastic leukemia | Leukemic Blast Count | Myc Translocation Evidence of | Molecular Diagnostic Techniques | Cytogenetic Analysis
Item
patients with b-cell all (l3 morphology or evidence of myc translocation by molecular or cytogenetic technique) are not eligible
boolean
C0279584 (UMLS CUI [1])
C2697913 (UMLS CUI [2])
C1511357 (UMLS CUI [3,1])
C0332120 (UMLS CUI [3,2])
C0949688 (UMLS CUI [4])
C0752095 (UMLS CUI [5])
Down Syndrome | Methotrexate
Item
patients with down syndrome are excluded due to the administration of methotrexate in block 2
boolean
C0013080 (UMLS CUI [1])
C0025677 (UMLS CUI [2])
Stem cell transplant Previous
Item
patients who have undergone prior stem cell transplantation (sct) are ineligible if:
boolean
C1504389 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
Stem cell transplant Time Interval
Item
they received sct less than 12 months prior to study entry
boolean
C1504389 (UMLS CUI [1,1])
C0872291 (UMLS CUI [1,2])
Therapeutic immunosuppression Graft-vs-Host Disease
Item
they are still receiving immunosuppression for the treatment of graft-versus-host disease (gvhd)
boolean
C0021079 (UMLS CUI [1,1])
C0018133 (UMLS CUI [1,2])
Mycoses
Item
they have active fungal infection at time of study entry
boolean
C0026946 (UMLS CUI [1])
Mycoses Filamentous Invasive Post Stem cell transplant
Item
they have had invasive filamentous fungal infection at any time post-sct
boolean
C0026946 (UMLS CUI [1,1])
C1979891 (UMLS CUI [1,2])
C0205281 (UMLS CUI [1,3])
C0687676 (UMLS CUI [1,4])
C1504389 (UMLS CUI [1,5])
Pregnancy | Breast Feeding
Item
pregnant or lactating females are ineligible as the medications used in this protocol could be harmful to unborn children and infants
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Relapse Extramedullary Isolated prior
Item
patients with prior isolated extramedullary relapse are ineligible
boolean
C0035020 (UMLS CUI [1,1])
C1517060 (UMLS CUI [1,2])
C0205409 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])